Solid tumor

Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors

🌟 Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors 🌟 Chinese biotech company CARsgen Therapeutics unveiled the latest data for its targeted Claudin18.2 autologous CAR-T cell candidate product, CT041, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This therapy is specifically designed for Claudin18.2-positive solid Read More

May 31st,2024 Solid tumor

New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer!

“New Breakthrough! Chinese Medical Team’s Remarkable Results with CLDN18.2 CAR-T Therapy for Pancreatic Cancer! 🎉” On May 25, 2024, the Journal of Clinical Oncology (JCO) published groundbreaking research by Professor Lin Shen’s team from Peking University Cancer Hospital on the application of CLDN18.2 CAR-T cell therapy for refractory metastatic pancreatic cancer, achieving impressive outcomes! This Read More

May 29th,2024 CAR-T , Solid tumor

Chinese Innovation in Medicine: A New Milestone in Small Cell Lung Cancer Treatment!

**Chinese Innovation in Medicine: A New Milestone in Small Cell Lung Cancer Treatment!** In the field of medicine, each new drug represents a leap forward in disease treatment, bringing new light and hope to patients. On May 9, 2024, the highly anticipated novel PD-L1 inhibitor, Bevosubab Single Monoclonal Antibody, officially received approval from the National Read More

May 14th,2024 Solid tumor

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

Menu

Solid tumor

Recent Posts